Updated May 18, 2026 · 631 articles
Educational guides about 13F filings, insider trading, institutional investing, and how to track smart money moves.
13F-NT is the notice filing institutional managers use when their qualifying assets are reported by another manager. It is a pointer, not a portfolio — and it is the single most-misread document in the 13F system.
WhaleScore combines AUM, portfolio concentration, holdings count, and filer-type classification into a 0-100 composite. This explainer walks through each input, the score bands, and the five misreadings that send first-time users astray.
Sarah MitchellForm 4 reports corporate insider transactions within 2 business days of execution. This explainer covers transaction codes, the dual-class Table I trap, cluster buying patterns, and 10b5-1 plan sales — plus how to use Form 4 data on 13F Insight.
Sarah MitchellForm 13F-HR is the quarterly SEC filing that institutional investment managers running over $100M in U.S. equities must file. This beginner's guide covers who files, what's inside, what it leaves out, and the six-step exercise to read your first 13F.
Sarah MitchellCrossing 5% ownership of a public company triggers a Schedule 13D filing within 10 days. This explainer covers Item 4 intent, the 13D vs 13G distinction, amendment patterns, and how to read 13D filings on 13F Insight.
Sarah Mitchell13F filings are the only consistent window into hedge fund positioning. This explainer walks through the five-step workflow — picking funds, reading the baseline, tracking quarter-over-quarter changes, cross-referencing 13D/Form 4 — plus the gaps 13F cannot fill.
Sarah MitchellFour times a year, managers running over $100M in equity assets file Form 13F-HR with the SEC. This guide covers the 45-day rule, what's inside the filing, the 13F-HR vs 13F-NT distinction, and the reading order to use during filing season.
Sarah MitchellWhether a top 13F holding represents real conviction depends on portfolio concentration. This explainer covers top-N concentration, holdings count, and how to read them against real examples from Pershing Square, Berkshire Hathaway, and Vanguard Group.
Sarah MitchellAssets under management means different things in different contexts: the firm's marketing number, the Form ADV regulatory number, and the 13F reported value are not the same. This explainer walks through what 13F AUM actually measures, and the five misreadings that get retail investors into trouble.
Sarah MitchellConsensus holdings are stocks owned by many institutional investors at the same time, with real portfolio weight. This explainer walks through how to compute them, how to use the 13F Insight consensus tool, and the three traps retail readers fall into.
Sarah MitchellMany tech founders hold Class B shares with superior voting rights that don't appear in standard stock screeners. Understanding the dual-class structure helps investors read Form 4 Table II correctly and avoid underestimating an insider's real economic interest in their company.
Sarah MitchellA Rule 10b5-1 trading plan lets corporate insiders sell shares on a prearranged schedule without violating insider trading rules. Understanding how these plans work helps investors correctly interpret insider Form 4 filings and separate mechanical selling from discretionary conviction shifts.
Sarah MitchellBlackstone, KKR & Co, Apollo Global Management, Brookfield Asset Management, plus Carlyle Group and Ares Management anchor US-traded alternative asset manager 13F positioning. Multi-year emerging private credit growth, fee-related earnings transition, plus emerging emerging retail alternative access drive distinctive institutional patterns.
Sarah MitchellJazz Pharmaceuticals, Royalty Pharma, Halozyme Therapeutics, Catalyst Pharmaceuticals, plus Organon and Viatris anchor US-traded mid-cap pharma 13F positioning. Multi-year emerging royalty financing dynamics, ENHANZE drug delivery, plus emerging emerging biosimilar plus generic dynamics drive distinctive institutional patterns.
Sarah MitchellVertex-CRISPR Therapeutics Casgevy, BioMarin Roctavian, Sarepta Elevidys, plus Beam Therapeutics, Editas Medicine, Intellia Therapeutics, and Verve Therapeutics anchor US-traded gene therapy 13F positioning. Multi-year emerging AAV gene therapy adoption, CRISPR gene editing, plus emerging emerging in-vivo gene editing drive distinctive institutional patterns.
Sarah MitchellSarepta Therapeutics, BioMarin Pharmaceutical, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, plus Vertex Pharmaceuticals and Insmed anchor US specialty biotech 13F positioning. Multi-year emerging rare disease economics, gene therapy adoption, plus emerging emerging RNAi plus antisense oligonucleotide platforms drive distinctive institutional patterns.
Sarah MitchellVeeva Systems, Oracle Health (Cerner post-acquisition), plus Epic (private), Doximity, Evolent Health, and Definitive Healthcare anchor US healthcare IT 13F positioning. Multi-year emerging life sciences SaaS, hospital EHR transition, plus emerging emerging AI-driven clinical documentation drive distinctive institutional patterns.
Sarah MitchellMcKesson, Cencora (formerly AmerisourceBergen), Cardinal Health, plus Henry Schein and Owens & Minor anchor US pharmaceutical distribution 13F positioning. Multi-year emerging specialty pharma growth, GLP-1 distribution dynamics, plus emerging emerging opioid settlement payments drive distinctive institutional patterns.
Sarah MitchellModerna, BioNTech, Pfizer (Comirnaty plus Prevnar), Merck Vaccines (within MRK, Gardasil plus Pneumovax), GSK (UK-domiciled US ADR), plus Sanofi anchor US-traded vaccine 13F positioning. Multi-year emerging COVID vaccine revenue normalization, RSV plus emerging combination flu-COVID vaccines, plus emerging emerging RFK Jr CDC ACIP regulatory dynamics drive distinctive institutional patterns.
Sarah Mitchell